Drug Trial Radar · NCT06649409
Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 5, 2024
Primary completion
Jun 29, 2024
Study completion Jul 6, 2024
Sponsor
- Lead sponsor
- Santhera PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate if the trial drug vamorolone is able to block a specific receptor in the body called mineralocorticoid receptor. This receptor helps to regulate salt and water balance.
Conditions
- Pharmacodynamic
Interventions
VamoroloneDrug
vamorolone 20 mg/kg single dose on Day 2
EplerenoneDrug
Eplerenone 200 mg single dose on Day 2
FludrocortisoneDrug
Fludrocortisone challenge on Days 1 to 3 (for all subjects): Day 1: -Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm Day 2: * Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm. * Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm. * Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm. Day 3: -Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of the Ratio of Sodium to Potassium (Na/K) in UrineTime frame: Day 1, Day 2 and Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuvisan GmbH
Neu-Ulm, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.